Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Biotech updates: Amicus, Aveo Oncology, Akcea Therapeutics, and Ionis Pharma

  • Adam Feuerstein

By Adam Feuerstein May 8, 2018

Reprints

Clinical reality strikes three biotech companies Tuesday, dampening their stock prices:

1. Hopes have dimmed that Amicus Therapeutics (FOLD) will be able to seek marketing approval for its Pompe disease drug in 2018. A cautious regulatory update issued Tuesday caused Amicus’ stock to fall 7 percent.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
When women are denied an abortion, their children fare…
When women are denied an abortion, their children fare worse than peers
New research may give geneticists a long-sought tool: a…
New research may give geneticists a long-sought tool: a targeted protein delivery device
British Columbia to bar Americans from buying Ozempic over…
British Columbia to bar Americans from buying Ozempic over supply concerns
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development
Medical device companies now need to prove to FDA…
Medical device companies now need to prove to FDA they’re protected against cyberattacks

Recommended Stories